Introduction
============

CM is a prevalent, disabling primary headache disorder. Most patients in CM clinical trials overuse AHM. The efficacy of prophylactic medications in CM patients without overuse of AHM is unclear.

Objective
=========

To evaluate the efficacy and tolerability of onabotulinumtoxinA in a chronic migraine (CM) subgroup without acute headache medication (AHM) overuse (MO-No).

Design/methods
==============

PREEMPT (two phase 3 studies: 24-week, double-blind, placebo-controlled, parallel-group phase, followed by 32-week, open-label phase) evaluated onabotulinumtoxinA for prophylaxis of headaches in CM (¡Ý15 days/month with headache lasting ¡Ý4 hours/day). Patients were stratified based on AHM use during 28-day baseline and randomized (1:1) to onabotulinumtoxinA (155-195U) or placebo every 12 weeks. Multiple headache-symptom measures were evaluated at Week 24, including mean change from baseline in headache-day frequency (primary). Pooled results from MO-No subgroup are reported.

Results
=======

480 (n=243 onabotulinumtoxinA; n=237 placebo) of 1384 patients met MO-No criteria. At Week 24, onabotulinumtoxinA treatment significantly reduced headache-day frequency compared to placebo (-8.8/onabotulinumtoxinA; -7.3/placebo: p=0.013). Significant improvements from baseline (p¡Ü0.027) also favored onabotulinumtoxinA at Week 24 for frequency of migraine-days, moderate/severe headache-days, total cumulative hours of headache on headache-days, and percent of patients with severe (¡Ý60) headache impact test (HIT-6) scores. Improvements in total HIT-6 and migraine-specific questionnaire scores all significantly favored onabotulinumtoxinA over placebo at Week 24 (p¡Ü0.032). Few patients in this subgroup discontinued because of an adverse event (AE); AEs were consistent with overall PREEMPT tolerability.

Conclusion/relevance
====================

OnabotulinumtoxinA is effective and well-tolerated for prophylaxis of headache in CM patients who do not overuse AHM.
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